Successful CoVID-19 Clinical Study Published in the Bahamas
Luminnova Health CoVID-19 Clinical Study
A study published in November 2022 utilizing the Luminnova protocols for CoVID-19 documented highly encouraging results. This investigation took place amidst the intense Delta COVID-19 surge in the Bahamas. The clinical data revealed that, despite the presence of underlying health conditions, exceptionally high viral loads, and severe COVID-19 symptoms, patients experienced an average recovery time of just 72 hours!
Excerpt of Study Abstract
“…Although our pilot subjects had significant co-morbidities, extremely high viral loads and moderately severe symptoms during the Delta phase of the pandemic, the response to treatment was highly encouraging. Rapid reductions in viral loads were observed and negative PCR tests were documented within a median of 4 days. These laboratory findings occurred in parallel with significant clinical improvement, mostly within 12–24 h of commencing the treatment protocol. There were no significant adverse effects and none of the subjects who completed the protocol required in-patient hospitalization. The outcomes were similarly encouraging at one-year follow-up with virtual absence of “long COVID” symptoms or of COVID-19 re-infection. Our results indicate that the protocols may be a safe and promising approach to challenging COVID-19 disease. Moreover, due its broad spectrum of activity, this approach has the potential to address the prevailing and future COVID-19 variants and other infections transmitted via the upper respiratory tract….”
Safety
There is often a trade off between effectiveness and safety. Fortunately, photodynamic therapy has been acknowledged as a safe treatment for many decades. This approach not only effectively eliminates microbes but also aids in alleviating the inflammation that can occur as a result of their destruction.
Methylene blue taken orally is another component of the Luminnova protocol for established covid infection. It is one of the oldest drugs with a long history of safety. However methylene blue should not be taken in combination with certain drugs or taken for prolonged periods in persons with a deficiency of the G6PD enzyme.
Broad Spectrum of Action
In addition to the CoVID-19 virus, photodynamic therapy is broadly active against many types of viruses, bacteria and fungal infections. As a result these protocols can be applied to many types of upper respiratory tract infections including the common cold and influenza.
Microbial Resistance Does not Develop
In addition to is broad spectrum of action and safety, one of the most important advantages of photodynamic therapy is that viruses and other microbes do not develop resistance to it. Consequently, this treatment approach has maintained its efficacy not only against the initial CoVID-19 strains but also against highly mutated variants.
Treatment Strategies
Based on the success of this study Luminnova Health has developed three treatment strategies against CoVID-19:
Prevention measures in the event of possible exposure
Early Intervention at the outset of any signs of upper respiratory infection
Treatment of established infection
To learn more click to watch the introductory video.